533 related articles for article (PubMed ID: 22183915)
1. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
2. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
3. Comparison of different bile acid-phospholipid conjugates in acute hepatitis.
Pathil A; Warth A; Chamulitrat W; Stremmel W
Eur J Clin Invest; 2012 Feb; 42(2):130-8. PubMed ID: 21707612
[TBL] [Abstract][Full Text] [Related]
4. Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent.
Chamulitrat W; Burhenne J; Rehlen T; Pathil A; Stremmel W
Hepatology; 2009 Jul; 50(1):143-54. PubMed ID: 19496180
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
6. Ursodeoxycholyl lysophosphatidylethanolamide inhibits lipoapoptosis by shifting fatty acid pools toward monosaturated and polyunsaturated fatty acids in mouse hepatocytes.
Chamulitrat W; Liebisch G; Xu W; Gan-Schreier H; Pathil A; Schmitz G; Stremmel W
Mol Pharmacol; 2013 Nov; 84(5):696-709. PubMed ID: 23974795
[TBL] [Abstract][Full Text] [Related]
7. Ursodeoxycholyl lysophosphatidylethanolamide protects against hepatic ischemia and reperfusion injury in mice.
Wang J; Deng X; Yi S; Pathil A; Zhang W; Setchell K; Stremmel W; Chamulitrat W
Shock; 2015 Apr; 43(4):379-86. PubMed ID: 25526375
[TBL] [Abstract][Full Text] [Related]
8. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
[TBL] [Abstract][Full Text] [Related]
9. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
10. Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-β1/Smad2/3 signalling.
Pathil A; Mueller J; Ludwig JM; Wang J; Warth A; Chamulitrat W; Stremmel W
Br J Pharmacol; 2014 Nov; 171(22):5113-26. PubMed ID: 25041068
[TBL] [Abstract][Full Text] [Related]
11. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency.
Kirsch R; Clarkson V; Verdonk RC; Marais AD; Shephard EG; Ryffel B; de la M Hall P
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 1):174-82. PubMed ID: 16706830
[TBL] [Abstract][Full Text] [Related]
12. The synthetic bile acid-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide suppresses TNFα-induced liver injury.
Pathil A; Warth A; Chamulitrat W; Stremmel W
J Hepatol; 2011 Apr; 54(4):674-84. PubMed ID: 21146893
[TBL] [Abstract][Full Text] [Related]
13. Anti-inflammatory properties of ursodeoxycholyl lysophosphatidylethanolamide in endotoxin-mediated inflammatory liver injury.
Ludwig JM; Zhang Y; Chamulitrat W; Stremmel W; Pathil A
PLoS One; 2018; 13(5):e0197836. PubMed ID: 29795632
[TBL] [Abstract][Full Text] [Related]
14. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet.
Koppe SW; Sahai A; Malladi P; Whitington PF; Green RM
J Hepatol; 2004 Oct; 41(4):592-8. PubMed ID: 15464239
[TBL] [Abstract][Full Text] [Related]
15. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
Hookman P; Barkin JS
Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
[TBL] [Abstract][Full Text] [Related]
16. Ursodeoxycholyl Lysophosphatidylethanolamide Protects Against CD95/FAS-Induced Fulminant Hepatitis.
Utaipan T; Otto AC; Gan-Schreier H; Chunglok W; Pathil A; Stremmel W; Chamulitrat W
Shock; 2017 Aug; 48(2):251-259. PubMed ID: 28060213
[TBL] [Abstract][Full Text] [Related]
17. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation.
Larter CZ; Yeh MM; Cheng J; Williams J; Brown S; dela Pena A; Bell-Anderson KS; Farrell GC
J Gastroenterol Hepatol; 2008 Feb; 23(2):267-75. PubMed ID: 17868330
[TBL] [Abstract][Full Text] [Related]
18. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes.
Larter CZ; Yeh MM; Williams J; Bell-Anderson KS; Farrell GC
J Hepatol; 2008 Sep; 49(3):407-16. PubMed ID: 18534710
[TBL] [Abstract][Full Text] [Related]
19. The immunosuppressant drug, thalidomide, improves hepatic alterations induced by a high-fat diet in mice.
Pinto Lde F; Compri CM; Fornari JV; Bartchewsky W; Cintra DE; Trevisan M; Carvalho Pde O; Ribeiro ML; Velloso LA; Saad MJ; Pedrazzoli J; Gambero A
Liver Int; 2010 Apr; 30(4):603-10. PubMed ID: 20088867
[TBL] [Abstract][Full Text] [Related]
20. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22.
Yang L; Zhang Y; Wang L; Fan F; Zhu L; Li Z; Ruan X; Huang H; Wang Z; Huang Z; Huang Y; Yan X; Chen Y
J Hepatol; 2010 Aug; 53(2):339-47. PubMed ID: 20452699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
